Glenmark Life Sciences is Incorporated in 2011, Company is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive Strengths
- Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
- Export products in Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationship with leading global generic companies.
- Proven track record of strong financial performance.
- High-quality product manufacturing with R&D infrastructure.
Glenmark Life Sciences LTD IPO Tentative Timetable
| Particular | Date |
| IPO Open Date | 27 July 2021 |
| IPO Close Date | 29 July 2021 |
| Allotment Date | 03 Aug 2021 |
| IPO Listing Date | 06 Aug 2021 |
Glenmark Life Sciences LTD IPO Details
| Issue Type | Book Built Issue IPO |
| Face Value | Rs. 2 Per Equity Share |
| IPO Price | Rs. 695 to Rs. 720 Per Equity Share |
| Market Lot | 20 Share |
| NSE Symbol | |
| BSE Symbol | |
| ISIN Code | |
| Listing At | NSE, & BSE |
| Issue Size | Approx. Rs. 1514 Crore. |
Glenmark Life Sciences Ltd IPO Lot Size
| Application | Lots | Shares | Amount |
| Minimum | 1 | 20 | Rs. 14400 |
| Maximum | 13 | 182 | Rs. 187200 |
Glenmark Life Sciences Ltd IPO Allotment Status
Click Here To Check IPO Allotment Status Glenmark Life Sciences Ltd IPO.
Click Here To Get ASBA Forms Glenmark Life Sciences Ltd IPO.
Company Financials:
| Particular | 31 March 2021 | 31 March 2020 | 31 March 2019 |
| Total Assets | 19970.75 | 17256.05 | 14753.95 |
| Total Revenue | 18859.76 | 15493.03 | 8868.65 |
| Profit After Tax | 3515.81 | 3130.98 | 1955.92 |
Company Promoters:
Glenmark Pharmaceuticals Limited is the promoter of the company.
Objects of this Issue:
The net IPO proceeds will be used for the following purposes;
- To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
- To finance capital expenditure requirements.
- To meet general corporate purposes.
Registrar & Company Details
| Company Contact Information | IPO Registrar |
| Glenmark Life Sciences Limited Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, Phone: +91 2189 234456/ +91 2189 Email: complianceofficer@glenmarklifesciences.com Website: http://www.glenmarklifesciences.com/ | KFintech Private Limited KFintech, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Gachibowli, Hyderabad, Telangana India – 500 032. Phone: 04067162222, 04079611000 Email: glenmark.ipo@kfintech.com Website: https://karisma.kfintech.com/ |
